ReviewCirculation research2023
The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy.
Review in Circulation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Prognostic value of neutrophil-to-lymphocyte ratio for the clinical outcomes of chronic kidney diseases: an update systematic review and meta-analysis.BMC nephrology · 2025Pooled it
- Proteomic Mendelian randomization and machine learning reveal causal plasma biomarkers in cardiorenal comorbidity.Renal failure · 2026Article
- Article
- Cardiac Biomarkers in Chronic Kidney Disease: Signal or Noise?Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Clonal hematopoiesis of indeterminate potential is associated with increased cardiovascular risk in chronic kidney disease.Clinical kidney journal · 2026Article
- Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial.ESC heart failure · 2026Article
- Uncovering core diseases in temporal trajectories of cardiovascular-kidney-metabolic (CKM) syndrome in UK Biobank: network-based study.Scientific reports · 2026Article
- Genetic evidence against a causal relationship between myocardial infarction and urological malignancies.The Canadian journal of urology · 2026Article
- Application of metabolomics in hypertension research: A bibliometric study and literature review.International journal of cardiology. Heart & vasculature · 2026Review
- Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches.Circulation. Heart failure · 2026Review
- Article
- Carotid plaque number and length as predictors of coronary heart disease in patients with early-stage chronic kidney disease.Frontiers in cardiovascular medicine · 2026Article
- Inflammatory markers and increased risk of chronic kidney disease in patients with coronary artery disease: findings from a multicenter cohort study.Frontiers in endocrinology · 2026Observational
- Heart Failure and Comorbidities (Chronic Kidney Disease, Diabetes, Obesity) Management: A Multidisciplinary Approach.Cardiorenal medicine · 2026Review
- Clinical determinants of agreement and discordance between stress SPECT and invasive coronary angiography.Frontiers in cardiovascular medicine · 2026Article
- Development of a nomogram for predicting incident heart failure and all-cause mortality in patients with chronic kidney disease: a 3-year follow-up study.Frontiers in medicine · 2026Article
- The relationship among inflammatory biomarkers, hyperuricemia and chronic kidney disease: analysis of the NHANES 2015-2020.Renal failure · 2025Article
- Cardiac LIM Protein, Kidney Fibrosis, and Vascular Change after Acute Cardiorenal Syndrome.Journal of the American Society of Nephrology : JASN · 2025Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic kidney disease (CKD) are at high risk to develop cardiovascular disease with its manifestations coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. In addition, the presence of CKD has a major impact on the prognosis of patients with cardiovascular disease, leading to an increased morbidity and mortality if both comorbidities are present. Therapeutic options including medical therapy and interventional treatment are often limited in patients with advanced CKD, and in most cardiovascular outcome trials, patients with advanced CKD have been excluded. Thus, in many patients, treatment strategies for cardiovascular disease need to be extrapolated from trials conducted in patients without CKD. The current article summarizes the epidemiology, clinical presentation, and treatment options for the most prevalent manifestations of cardiovascular disease in CKD and discusses the currently available treatment options to reduce morbidity and mortality in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.